pemvidutide
pemvidutide: developed by 1 company · 2 clinical trials tracked.
pemvidutide evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could pemvidutide → ALT affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (3)
| Company | Phase |
|---|---|
| Altimmune, Inc. (ALT) Alcohol-associated Liver Disease; Alcohol Use Disorder (AUD) | Phase 2 |
| Altimmune, Inc. (ALT) Alcohol-associated Liver Disease; Alcohol Use Disorder (AUD) | Phase 2 |
| Altimmune, Inc. (ALT) Alcohol-associated Liver Disease; Alcohol Use Disorder (AUD) | Phase 2 |
Clinical Trials (2)
RESTORE TRIAL: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)
Primary endpoint: Relative (%) reduction in liver stiffness by VCTE compared to baseline
RECLAIM STUDY: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight
Primary endpoint: Change from baseline in the average number of heavy drinking days per week
Frequently asked questions
Who is developing pemvidutide?
pemvidutide is being developed by Altimmune, Inc..
How many clinical trials involve pemvidutide?
BioSniper tracks 2 clinical trials involving pemvidutide.